{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:48:55Z","timestamp":1788371335826,"version":"build-2803163510"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":71,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Tianjin Natural Science Foundation Project","award":["25JCZDJC00830"],"award-info":[{"award-number":["25JCZDJC00830"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08302-y","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T13:05:03Z","timestamp":1779714303000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long-term follow-up results of anti-BCMA CAR-T cell therapy combined with autologous hematopoietic stem cell transplantation in relapsed\/refractory multiple myeloma with extramedullary disease"],"prefix":"10.1186","volume":"24","author":[{"given":"Xin","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyan","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuquan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3646-4953","authenticated-orcid":false,"given":"Qi","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"issue":"3","key":"8302_CR1","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/s41375-021-01453-5","volume":"36","author":"M Binder","year":"2022","unstructured":"Binder M, Nandakumar B, Rajkumar SV, Kapoor P, Buadi FK, Dingli D, et al. Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. Leukemia. 2022;36(3):801\u20138.","journal-title":"Leukemia"},{"issue":"10272","key":"8302_CR2","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","volume":"397","author":"NWCJ van de Donk","year":"2021","unstructured":"van de Donk NWCJ, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397(10272):410\u201327.","journal-title":"Lancet"},{"issue":"4","key":"8302_CR3","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1172\/JCI129205","volume":"130","author":"SA Minnie","year":"2020","unstructured":"Minnie SA, Hill GR. Immunotherapy of multiple myeloma. J Clin Invest. 2020;130(4):1565\u201375.","journal-title":"J Clin Invest"},{"key":"8302_CR4","doi-asserted-by":"publisher","first-page":"101929","DOI":"10.1016\/j.ctrv.2019.101929","volume":"82","author":"I Ntanasis-Stathopoulos","year":"2020","unstructured":"Ntanasis-Stathopoulos I, Gavriatopoulou M, Kastritis E, Terpos E, Dimopoulos MA. Multiple myeloma: role of autologous transplantation. Cancer Treat Rev. 2020;82:101929.","journal-title":"Cancer Treat Rev"},{"key":"8302_CR5","doi-asserted-by":"publisher","first-page":"m3176","DOI":"10.1136\/bmj.m3176","volume":"370","author":"UA Shah","year":"2020","unstructured":"Shah UA, Mailankody S. Emerging immunotherapies in multiple myeloma. BMJ. 2020;370:m3176.","journal-title":"BMJ"},{"issue":"3","key":"8302_CR6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41408-022-00643-3","volume":"12","author":"J Blad\u00e9","year":"2022","unstructured":"Blad\u00e9 J, Beksac M, Caers J, Jurczyszyn A, von Lilienfeld-Toal M, Moreau P, et al. Extramedullary disease in multiple myeloma: a systematic literature review. Blood Cancer J. 2022;12(3):45.","journal-title":"Blood Cancer J"},{"issue":"16suppl","key":"8302_CR7","doi-asserted-by":"publisher","first-page":"8002","DOI":"10.1200\/JCO.2023.41.16_suppl.8002","volume":"41","author":"YC Cohen","year":"2023","unstructured":"Cohen YC, Morillo D, Gatt ME, Sebag M, Kim K, Min C-K, et al. First results from the RedirecTT-1 study with teclistamab (tec)+talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed\/refractory multiple myeloma (RRMM). J Clin Oncol. 2023;41(16suppl):8002.","journal-title":"J Clin Oncol"},{"issue":"4","key":"8302_CR8","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389(4):335\u2013447.","journal-title":"N Engl J Med"},{"issue":"10","key":"8302_CR9","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1002\/ajh.27023","volume":"98","author":"S Zanwar","year":"2023","unstructured":"Zanwar S, Ho M, Lin Y, Kapoor P, Binder M, Buadi FK, et al. Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myeloma. Am J Hematol. 2023;98(10):1540\u20139.","journal-title":"Am J Hematol"},{"issue":"1","key":"8302_CR10","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3324\/haematol.2019.219139","volume":"105","author":"V Montefusco","year":"2020","unstructured":"Montefusco V, Gay F, Spada S, De Paoli L, Di Raimondo F, Ribolla R, et al. Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs. Haematologica. 2020;105(1):193\u2013200.","journal-title":"Haematologica"},{"issue":"24","key":"8302_CR11","doi-asserted-by":"publisher","first-page":"6106","DOI":"10.3390\/cancers14246106","volume":"14","author":"X Yue","year":"2022","unstructured":"Yue X, He D, Zheng G, Yang Y, Han X, Li Y, et al. Analysis of high-risk extramedullary relapse factors in newly diagnosed MM patients. Cancers (Basel). 2022;14(24):6106.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"8302_CR12","doi-asserted-by":"publisher","first-page":"2281657","DOI":"10.1080\/07853890.2023.2281657","volume":"55","author":"J Wang","year":"2023","unstructured":"Wang J, Shen N, Shen X, Zhang R, Jin Y, Li J, et al. Survival trends and prognostic factors of patients with newly diagnosed multiple myeloma accompanied with extramedullary disease. Ann Med. 2023;55(2):2281657.","journal-title":"Ann Med"},{"issue":"1","key":"8302_CR13","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1080\/16078454.2021.2019364","volume":"27","author":"Y Li","year":"2022","unstructured":"Li Y, Ji J, Lu H, Li J, Qu X. Pomalidomide-based therapy for extramedullary multiple myeloma. Hematology. 2022;27(1):88\u201394.","journal-title":"Hematology"},{"issue":"1","key":"8302_CR14","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13045-024-01555-4","volume":"17","author":"S Zanwar","year":"2024","unstructured":"Zanwar S, Sidana S, Shune L, Puglianini OC, Pasvolsky O, Gonzalez R, et al. Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel. J Hematol Oncol. 2024;17(1):42.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"8302_CR15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1182\/blood.2024025945","volume":"145","author":"S Sidana","year":"2025","unstructured":"Sidana S, Patel KK, Peres LC, Bansal R, Kocoglu MH, Shune L, et al. Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma. Blood. 2025;145(1):85\u201397.","journal-title":"Blood"},{"key":"8302_CR16","doi-asserted-by":"publisher","first-page":"720571","DOI":"10.3389\/fimmu.2021.720571","volume":"12","author":"H Deng","year":"2021","unstructured":"Deng H, Liu M, Yuan T, Zhang H, Cui R, Li J, et al. Efficacy of humanized anti-BCMA CAR T cell therapy in relapsed\/refractory multiple myeloma patients with and without extramedullary disease. Front Immunol. 2021;12:720571.","journal-title":"Front Immunol"},{"issue":"3","key":"8302_CR17","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","volume":"32","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(3):309\u201322.","journal-title":"Ann Oncol"},{"issue":"26","key":"8302_CR18","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863\u20139.","journal-title":"J Clin Oncol"},{"issue":"4","key":"8302_CR19","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transpl. 2019;25(4):625\u201338.","journal-title":"Biol Blood Marrow Transpl"},{"key":"8302_CR20","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Bethesda (MD). U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute; 2017. Nov 27."},{"issue":"4","key":"8302_CR21","doi-asserted-by":"publisher","first-page":"606","DOI":"10.3390\/cells11040606","volume":"11","author":"S Mor\u00e8","year":"2022","unstructured":"Mor\u00e8 S, Corvatta L, Manieri VM, Martino MD, Marchesi F, Velardi A, et al. Autologous stem cell transplantation in multiple myeloma: where are we and where do we want to go? Cells. 2022;11(4):606.","journal-title":"Cells"},{"issue":"3","key":"8302_CR22","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1182\/bloodadvances.2019000524","volume":"4","author":"KK Nishimura","year":"2020","unstructured":"Nishimura KK, Barlogie B, van Rhee F, Epstein J, Waheed S, Petty N, et al. Long-term outcomes after autologous stem cell transplantation for multiple myeloma. Blood Adv. 2020;4(3):422\u201331.","journal-title":"Blood Adv"},{"key":"8302_CR23","doi-asserted-by":"publisher","first-page":"925818","DOI":"10.3389\/fonc.2022.925818","volume":"12","author":"AL Keller","year":"2022","unstructured":"Keller AL, Sherbenou DW, Forsberg PA, Cowan AJ, Green DJ, Lin Y, et al. Harnessing the T cell to treat multiple myeloma: dawn of a new therapeutic paradigm. Front Oncol. 2022;12:925818.","journal-title":"Front Oncol"},{"issue":"8","key":"8302_CR24","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1007\/s00277-024-05641-y","volume":"103","author":"TL Hsu","year":"2024","unstructured":"Hsu TL, Tsai CK, Liu CY, Chang CS, Wu HC, Chen PM, et al. Risk factors of early disease progression and decreased survival for multiple myeloma patients after upfront autologous stem cell transplantation. Ann Hematol. 2024;103(8):2893\u2013904.","journal-title":"Ann Hematol"},{"issue":"10","key":"8302_CR25","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1038\/bmt.2017.165","volume":"52","author":"L Kumar","year":"2017","unstructured":"Kumar L, Gogi R, Patel AK, Sharma A, Raina V, Gupta R, et al. Multiple myeloma with extramedullary disease: impact of autologous stem cell transplantation on outcome. Bone Marrow Transpl. 2017;52(10):1473\u20135.","journal-title":"Bone Marrow Transpl"},{"issue":"3","key":"8302_CR26","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1002\/hon.3123","volume":"41","author":"J Kauer","year":"2023","unstructured":"Kauer J, Sester LS, Kriegsmann K, Weinhold N, Ober M, M\u00fcller-Tidow C, et al. Cyclophosphamide etoposide dexamethasone as salvage and bridging therapy in relapsed refractory and extramedullary multiple myeloma. Hematol Oncol. 2023;41(3):453\u201362.","journal-title":"Hematol Oncol"},{"issue":"5","key":"8302_CR27","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/bjh.16764","volume":"191","author":"D Kazandjian","year":"2020","unstructured":"Kazandjian D, Landgren O. Biology and treatment of extramedullary disease in multiple myeloma. Br J Haematol. 2020;191(5):692\u2013703.","journal-title":"Br J Haematol"},{"key":"8302_CR28","doi-asserted-by":"publisher","first-page":"101465","DOI":"10.1016\/j.tranon.2022.101465","volume":"22","author":"Y Li","year":"2022","unstructured":"Li Y, Li J, Lu H, Qu X. Clinical characteristics and outcomes of extramedullary multiple myeloma: a real-world retrospective analysis. Transl Oncol. 2022;22:101465.","journal-title":"Transl Oncol"},{"issue":"10","key":"8302_CR29","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1038\/s41409-025-02675-2","volume":"60","author":"S Iacobelli","year":"2025","unstructured":"Iacobelli S, Griggio V, Ciceri F, Bruno B, Milone G, Marcatti M, et al. Long-term outcomes of tandem versus single autologous transplantation in high-risk multiple myeloma: a retrospective EBMT study. Bone Marrow Transpl. 2025;60(10):1361\u20138.","journal-title":"Bone Marrow Transpl"},{"issue":"3","key":"8302_CR30","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/s41409-024-02490-1","volume":"60","author":"N Grieb","year":"2025","unstructured":"Grieb N, Schreder M, Kauer J, Knop S, Rasche L, Einsele H, et al. Prognostic impact of extramedullary disease in multiple myeloma patients receiving BCMA-directed CAR T-cell therapy. Bone Marrow Transpl. 2025;60(3):335\u201345.","journal-title":"Bone Marrow Transpl"},{"issue":"8","key":"8302_CR31","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705\u201316.","journal-title":"N Engl J Med"},{"issue":"11","key":"8302_CR32","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023;388(11):1002\u201314.","journal-title":"N Engl J Med"},{"issue":"4","key":"8302_CR33","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389(4):335\u201347.","journal-title":"N Engl J Med"},{"key":"8302_CR34","doi-asserted-by":"publisher","first-page":"115374","DOI":"10.1016\/j.ejca.2025.115374","volume":"220","author":"Y Wang","year":"2025","unstructured":"Wang Y, Liu Y, Zhang X, Chen L, Li J, Zhao Y, et al. Real-world outcomes of extramedullary multiple myeloma in China: a multicenter retrospective study. Eur J Cancer. 2025;220:115374.","journal-title":"Eur J Cancer"},{"issue":"3","key":"8302_CR35","doi-asserted-by":"publisher","first-page":"e009876","DOI":"10.1136\/jitc-2024-010687","volume":"13","author":"C Jin","year":"2025","unstructured":"Jin C, Chen R, Fu S, Wang Y, Li J, Zhang Y, et al. Long-term follow-up of BCMA CAR-T cell therapy in patients with relapsed\/refractory multiple myeloma. J Immunother Cancer. 2025;13(3):e009876.","journal-title":"J Immunother Cancer"},{"key":"8302_CR36","doi-asserted-by":"publisher","first-page":"1663814","DOI":"10.3389\/fonc.2025.1663814","volume":"15","author":"Z Abuhelwa","year":"2025","unstructured":"Abuhelwa Z, Almomen A, Alsharif F, Alzahrani M, Aljurf M. Outcomes of CAR T-cell therapy in high-risk multiple myeloma: a single-center experience. Front Oncol. 2025;15:1663814.","journal-title":"Front Oncol"},{"issue":"Suppl 1","key":"8302_CR37","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1182\/blood-2023-177749","volume":"142","author":"D Pan","year":"2023","unstructured":"Pan D, Mouhieddine TH, Fu W, Lesokhin A, Mailankody S, Korde N, et al. Outcomes after CAR T cells in multiple myeloma patients with extramedullary and paramedullary disease. Blood. 2023;142(Suppl 1):1006.","journal-title":"Blood"},{"issue":"9","key":"8302_CR38","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1038\/s41591-023-02496-0","volume":"29","author":"Y Lin","year":"2023","unstructured":"Lin Y, Raje N, Berdeja JG, Siegel DS, Madduri D, Liedtke M, et al. Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial. Nat Med. 2023;29(9):2286\u201394.","journal-title":"Nat Med"},{"issue":"1","key":"8302_CR39","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13045-025-01713-2","volume":"18","author":"H Yao","year":"2025","unstructured":"Yao H, Li Y, Wang Q, Zhang L, Chen B, Zhou D, et al. Biomarkers predicting response to BCMA-targeted CAR T therapy in extramedullary multiple myeloma. J Hematol Oncol. 2025;18(1):56.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"8302_CR40","doi-asserted-by":"publisher","first-page":"456","DOI":"10.3390\/curroncol32030182","volume":"32","author":"M Ho","year":"2025","unstructured":"Ho M, Zanwar S, Lin Y, Kapoor P, Binder M, Buadi FK, et al. Management of extramedullary disease in multiple myeloma: current challenges and future directions. Curr Oncol. 2025;32(3):456\u201368.","journal-title":"Curr Oncol"},{"issue":"18","key":"8302_CR41","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380(18):1726\u201337.","journal-title":"N Engl J Med"},{"issue":"4","key":"8302_CR42","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.3390\/jcm9041195","volume":"9","author":"LE Franssen","year":"2020","unstructured":"Franssen LE, Stege CAM, Zweegman S, Mutis T, Groen RWJ. Resistance mechanisms towards CD38-directed antibody therapy in multiple myeloma. J Clin Med. 2020;9(4):1195.","journal-title":"J Clin Med"},{"issue":"5","key":"8302_CR43","first-page":"e127807","volume":"5","author":"JK Bailur","year":"2020","unstructured":"Bailur JK, McCachren SS, Doxie DB, Pendleton KM, Stefanek SC, Harville TO, et al. Early alterations in stem-like\/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy. JCI Insight. 2020;5(5):e127807.","journal-title":"JCI Insight"},{"issue":"9","key":"8302_CR44","doi-asserted-by":"publisher","first-page":"5242","DOI":"10.3390\/ijms23095242","volume":"23","author":"I Lagreca","year":"2022","unstructured":"Lagreca I, Riva G, Nasillo V, Dall\u2019Olio FG, Potenza L, Fiorentini S, et al. The role of T cell immunity in monoclonal gammopathy and multiple myeloma: from immunopathogenesis to novel therapeutic approaches. Int J Mol Sci. 2022;23(9):5242.","journal-title":"Int J Mol Sci"},{"key":"8302_CR45","doi-asserted-by":"crossref","unstructured":"Andr\u00e9 AP, Ana B, Pablo G, Paula A, Rafael H, Balaguer-Rosell\u00f3 A, et al. Patterns of immune recovery after axicabtagene ciloleucel for aggressive B-cell lymphoma. HemaSphere. 2025;9(10):e70229.","DOI":"10.1002\/hem3.70229"},{"issue":"5","key":"8302_CR46","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41408-021-00469-5","volume":"11","author":"PJ Teoh","year":"2021","unstructured":"Teoh PJ, Chng WJ. CAR T-cell therapy in multiple myeloma: more room for improvement. Blood Cancer J. 2021;11(5):84.","journal-title":"Blood Cancer J"},{"key":"8302_CR47","doi-asserted-by":"publisher","first-page":"651288","DOI":"10.3389\/fimmu.2021.651288","volume":"12","author":"SA Minnie","year":"2021","unstructured":"Minnie SA, Hill GR. Autologous stem cell transplantation for myeloma: cytoreduction or an immunotherapy? Front Immunol. 2021;12:651288.","journal-title":"Front Immunol"},{"key":"8302_CR48","doi-asserted-by":"publisher","first-page":"108007","DOI":"10.1016\/j.pharmthera.2021.108007","volume":"232","author":"T Choi","year":"2022","unstructured":"Choi T, Kang Y. Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma. Pharmacol Ther. 2022;232:108007.","journal-title":"Pharmacol Ther"},{"issue":"2","key":"8302_CR49","first-page":"61","volume":"28","author":"M Janakiram","year":"2022","unstructured":"Janakiram M, Arora N, Bachanova V, Callander NS, Costa LJ, Dhakal B, et al. Novel cell and immune engagers in optimizing tumor-specific immunity post-autologous transplantation in multiple myeloma. Transpl Cell Ther. 2022;28(2):61\u20139.","journal-title":"Transpl Cell Ther"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08302-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08302-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08302-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:02:56Z","timestamp":1785855776000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08302-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8302"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08302-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8582254\/v1","asserted-by":"object"}]},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]},"assertion":[{"value":"12 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Medical Ethics Committee of the Department of Hematology, Tianjin First Center Hospital (Tianjin, China). (Approved No. of ethic committee: 2020N028KY). The Clinical trial in our study was registered at\n                      \n                      as ChiCTR2000033925.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None declared.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"990"}}